The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.
The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study. Ondansetron was given as three 8 mg intravenous doses (0, 4 and 8 h) and metoclopramide as an intravenous loading dose (3 mg/kg) followed by a maintenance dose of 0.5 mg/kg/h for 8 h. Therapeutic outcomes and full utilisation costs, that is nursing time, material costs, in addition to drug acquisition prices were recorded for each antiemetic for 24 h following chemotherapy. The cost per successfully treated patient (< or = 1 emetic episode and no adverse events) was 95.20 pounds for ondansetron and 92.18 pounds for metoclopramide. The results of the study therefore suggest that for the control of acute emesis due to highly emetogenic chemotherapy ondansetron and metoclopramide are equally cost-effective treatments.
Royal Marsden Hospital, Sutton, Surrey, UK.
D
D
Cunningham
M
M
Gore
N
N
Davidson
M
M
Miocevich
M
M
Manchanda
N
N
Wells
D000970:Antineoplastic Agents / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017723:Drug Utilization Review; D005260:Female; D006761:Hospitals; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000191:economics* / Q000627:therapeutic use; D008875:Middle Aged; D017294:Ondansetron / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome; D006113:United Kingdom; D014839:Vomiting / Q000139:chemically induced / Q000191:economics* / Q000517:prevention & control
D000970:Antineoplastic Agents; D017294:Ondansetron; D008787:Metoclopramide